News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 16, 2023
ALS Phase 2b PARADIGM Trial Completed Patient Enrollment Topline results expected in Q-4 2023 Cash runway beyond topline clinical study readouts, into Q-2 2024 CAMBRIDGE, Mass., Aug. 16, 2023...
-
Jul 17, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only event. CAMBRIDGE, Mass., July 17, 2023...
-
Jul 11, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it will participate in two upcoming conferences...
-
Jul 6, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...
-
Jun 22, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase...
-
Jun 1, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced financial results for the quarter ended March 31,...
-
May 15, 2023
96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extension Topline results expected Q4 2023 CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/...
-
May 2, 2023
Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individuals NeuroSense's...
-
Apr 17, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...
-
Mar 27, 2023
In vitro studies to test the effects of PrimeC on key pathways involved in ALS including TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress Preliminary results...
-
Mar 23, 2023
Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept...
-
Mar 22, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing...
-
Mar 16, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik and...
-
Mar 14, 2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest...
-
Feb 13, 2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a corporate update video from its Founder and CEO...
-
Feb 9, 2023
QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind proof-of-concept...
-
Feb 8, 2023
PARADIGM protocol is approved in four countries: Israel, Italy, Canada, and Germany Topline results expected in H2 2023 CAMBRIDGE, Mass., Feb. 8, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
-
Feb 6, 2023
Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023 CAMBRIDGE, Mass., Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
-
Jan 19, 2023
Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform Phase 2 double-blind proof-of-concept clinical study...
-
Dec 1, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended...
-
Nov 16, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian...
-
Nov 15, 2022
NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy Follows a successful U.S. pharmacokinetic (PK) study which...
-
Oct 27, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences....
-
Oct 21, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering...
-
Oct 18, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of Founder and...